While initial public offerings get most of the splash, public companies also are raking in cash with follow-on offerings. How long will the Wall Street spigot stay open?
NEW YORK, NY / ACCESSWIRE / March 30, 2020 / Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 30, 2020 ...
Q3 2019 Titan Pharmaceuticals Inc Earnings Call
SOUTH SAN FRANCISCO, Calif., Oct. 22, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (TTNP) today announced that it has two poster presentations on Probuphine (buprenorphine) implant, Titan's novel 6-month maintenance treatment for Opioid Use Disorder ("OUD") in eligible patients, at the 10th American Conference on Pharmacometrics taking place on October 20-23, 2019 in Orlando, FL. The poster presentations will provide details of the results from computer modeling studies that assessed the population pharmacokinetic ("PK") parameters, exposure-response profiles, and drug-drug interaction ("DDI") potential of the patient plasma levels of buprenorphine during treatment with Probuphine subdermal implants.
Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) today announced that its first quarter 2020 financial results will be released on Friday, May 15, 2020.
By John Vandermosten, CFA NASDAQ:TTNP READ THE FULL TTNP RESEARCH REPORT During 2019 and to date, Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) has expanded its distribution network to cover the entire United States working in partnership with several well-known specialty pharmaceutical players. The company also improved its distribution process, taking what had been up to three months to deliver a
Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) today announced that at its recent annual stockholders meeting, Kate DeVarney, Ph.D., its Executive Vice President and Chief Scientific Officer, was elected to the Company's Board of Directors.
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced that management will present an update on the Company's business at the first annual BioTuesdays Pre-JPM Virtual Conference on Tuesday, December 10, 2019 at 3:00 p.m. EST / 12:00 p.m. PST.
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today reported financial results for the fourth quarter and full year ended December 31, 2019 and provided an update on its business.
It is a pleasure to report that the Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) is up 66% in the last quarter. But the...
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced it has entered into a securities purchase agreement with certain accredited institutional investors to purchase approximately $2.2 million of its common stock in a registered direct offering and warrants to purchase shares of common stock in a concurrent private placement. The combined purchase price for one share of common stock and each warrant will be $0.25.
Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) today announced that it has signed an agreement for Probuphine (buprenorphine) implant to be included on the Federal Supply Schedule ("FSS"), providing U.S. veterans and other federal government agencies with access to Titan's novel 6-month maintenance treatment for Opioid Use Disorder ("OUD") in eligible patients. The final FSS contract is effective January 15, 2020 and has a five-year term. The FSS contract will extend access to Probuphine to over nine million VA beneficiaries and others within the federal system.
In 2015 Sunil Bhonsle was appointed CEO of Titan Pharmaceuticals, Inc. (NASDAQ:TTNP). This report will, first, examine...
By John Vandermosten, CFA NASDAQ:TTNP READ THE FULL TTNP RESEARCH REPORT Third Quarter 2019 Financial and Operational Results During the third quarter and to date, Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) has expanded its network to include CVS Caremark, raised additional capital to support its sales and marketing efforts, received approval for additional NIDA funding and presented a pair of
SOUTH SAN FRANCISCO, Calif. , Nov. 7, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) will announce its third quarter 2019 financial results after market close on Thursday, November 14, ...
Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) today announced that, since January 1, 2020, it has received proceeds of approximately $5.9 million as a result of the exercise of approximately 26.2 million previously issued Class B common share purchase warrants (the "Class B Warrants").
Q4 2019 Titan Pharmaceuticals Inc Earnings Call
SOUTH SAN FRANCISCO, Calif. , Nov. 14, 2019 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today reported financial results for the third quarter ended September 30, 2019 and provided an update ...
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) today announced that its fourth quarter and full year 2019 financial results will be released after market close on Monday, March 30, 2020.
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") today reported financial results for the first quarter ended March 31, 2020 and provided an update on its business.